retatrutide
Regeneration vs degeneration — where this fits
The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.
Why it would work (logic chain)
No mechanism chain catalogued yet.
How many people take it
There is no reliable global count of how many people take this compound. That number is not in this ledger.
What we can count from this ledger:
- 0 anecdote source(s) (posts, threads, comments)
- 0 anecdote-tier claim(s) derived from them
Logic: Without catalogued Reddit/X posts, this article cannot answer how many people take it — only what studies exist.
Evidence inventory
This is a count of what is in this ledger — not a claim about all research worldwide.
- Scientific sources catalogued (PubMed, trials, reviews): 10
- Claims tagged human evidence: 0
- Claims tagged preclinical (animal/lab): 0
- Claims tagged anecdotal: 0
- Reddit posts catalogued: 0
- X posts catalogued: 0
- Other anecdote sources (YouTube, Instagram, etc.): 0
- Total sources in chain: 10
Logic: Studies exist in the ledger, but none are graded as strong human proof for the uses people discuss online. Animal and lab work is not the same as proof in people.
Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.
Quantified confidence (this ledger): 0.25 / 1.00 — low — animal and anecdote heavy
Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.
What scientists say
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial (source s1)
2026 Lancet phase 3 trial (TRANSCEND-T2D-1) on retatrutide efficacy/safety in T2D patients.
Evidence type: Published research.
Efficacy and safety of retatrutide for the treatment of obesity (source s2)
2025 systematic review on retatrutide safety/efficacy for obesity.
Evidence type: Published research.
Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis (source s3)
2025 meta-analysis showing retatrutide superior to placebo for obesity.
Evidence type: Published research.
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist, for the treatment of obesity: a systematic review and meta-analysis (source s4)
2025 meta-analysis on retatrutide for obesity treatment.
Evidence type: Published research.
Retatrutide-A Game Changer in Obesity Pharmacotherapy (source s5)
2025 review on retatrutide mechanisms, efficacy, and safety.
Evidence type: Published research.
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial (source s6)
2025 phase 2 substudy on retatrutide effects on body composition in T2D.
Evidence type: Published research.
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) (source s7)
Ongoing TRIUMPH-3 phase 3 trial (last update 2026) for retatrutide in obesity with CVD.
Evidence type: Published research.
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials (source s8)
Describes the design of Phase 3 TRIUMPH trials for retatrutide in obesity, OSA, and knee OA using a basket trial approach.
Evidence type: Published research.
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (source s9)
Phase 2b trial examining retatrutide's impact on renal function in overweight/obese patients with CKD ± T2D.
Evidence type: Published research.
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8) (source s10)
Phase 3b trial of retatrutide vs placebo for weight reduction in obesity/overweight without T2D.
Evidence type: Published research.
---
Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.
Ask this article · 2 suggested prompts
Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.